Nelli® is CE-marked as a class I medical device according to Directive 93/42/EEC.
Nelli® is commercially available in the EU.
Nelli® has been granted Breakthrough Device Designation by
the FDA and is an investigational device in the USA.
See
Fast and accurate seizure detection at home and in the hospital
Learn
Objective and easy-to-use data provided by AI and reviewed by a human expert
Improve
Better diagnostics and improved follow upNelli® analyses and quantifies motion and sound activity that suggest seizure behavior in adults and children.
Nelli® consists of a Personal Recording Unit (PRU) with camera and microphone, a cloud-based server for patient data analysis and a web-based dashboard for viewing the results remotely.
Video and audio recordings of the patient are captured at home or in a healthcare facility. Relevant motions and sounds are analysed by trained AI algorithms and lead to a interactive report and scattergram that can be reviewed by the physician.
Research supports accuracy of seizure detection
In a study comparing Nelli® to VEEG in 230 patients
-
88%
Sensitivity for all motor seizures1
-
95.2%
Sensitivity for convulsive seizures1
-
6.48
False detection rate per hour for all motor seizures 1
1 Rai P. et al. Automated analysis and detection of epileptic seizures in video recordings using Artificial Intelligence. Frontiers in Neuroinformatics (2024).
In a study with 104 patients monitored for an average of 29 days, using Nelli® led to
-
>86%
Clinical decisions2
-
83
Differential diagnosis of all patients with recorded epidoses2
-
68%
Therapeutic interventions or adjustments2
2 Basnyat P. et al. Clinical utility of a video/audio-based epilepsy monitoring system Nelli. Epilepsy & Behavior (2022).
